Following its win on appeal, AstraZeneca Pharmaceuticals failed to persuade a federal judge to award it attorney fees for its defense against allegations that it violated Teva Pharmaceutical Industries’ patent for a component to drugs that lower cholesterol.
AstraZeneca prevailed in district court as well as on appeal in the Federal Circuit, but did not convince U.S. District Judge William H. Yohn Jr. of the Eastern District of Pennsylvania that the case was “exceptional,” which would have warranted the awarding of fees.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
